Rapid Urine Test Evaluated for Helicobacter Pylori Infection
|
By LabMedica International staff writers Posted on 26 Jun 2014 |

Image: Rapirun Helicobacter pylori Antibody Stick. The urine sample is considered positive when two red bands at the test line and control line (arrows) are observed after 15 minutes and is considered negative when only the control line is observed. The absence of a control line indicates an invalid result (Photo courtesy of Duc T Quach).

Image: The PyloriTek rapid urease test to detect Helicobacter pylori (Photo courtesy of Serim Research Co.).
A rapid urine test based on enzyme-linked immunosorbent assay (ELISA) has been developed for the detection of anti-Helicobacter Pylori antibodies in urine.
Several methods to diagnose H. pylori infection have been developed, among which the urea breath test (UBT) is currently regarded as the most accurate assay, but the UBT is still expensive and not widely available in many countries.
Scientists at the Ho Chi Minh City Medicine and Pharmacy University (Vietnam) working with Japanese colleagues, enrolled 200 patients undergoing upper gastrointestinal endoscopy from October 2012 to December 2012. Three biopsies were taken from each patient: two for histologic examination and one for the rapid urease test (RUT).
The biopsy for RUT was taken from the greater curvature of the corpus, about 2 cm above the atrophic border. This biopsy location has been reported to optimize the sensitivity of the PyloriTek RUT to detect H. pylori (Serim Research Co.; Elkhart, IN, USA). Urine samples were collected and were processed within one hour of collection for the detection of antibodies against H. pylori using the Rapirun Helicobacter pylori Antibody Stick (Otsuka Pharmaceutical Co., Ltd.; Tokyo, Japan). The test measures human immunoglobulin G (IgG) antibodies against H. pylori in urine using the principle of immunochromatography.
Of the 200 patients, 111 (55.5%) were diagnosed as being H. pylori positive. The sensitivity, specificity, and accuracy of the Rapirun Stick test were 84.7%, 89.9%, and 87.0%, respectively. There were 17 (8.5%) false-negative patients and 9 (4.5%) false-positive patients. Of the 24 patients with gastro-duodenal ulcer, 22 (91.7%) had H. pylori infection. However, 7 of 22 (31.8%) patients with reflux esophagitis also had the infection.
The authors demonstrated the usefulness of the Rapirun Stick test for the diagnosis of H. pylori infection in a Vietnamese population and the sensitivity, specificity, and accuracy of the Rapirun Stick test were high. In several patients, RUT and histologic examination produced false-negative or false-positive results, leading to the possible misdiagnosis of H. pylori infection. The study was published on May 7, 2014, in the World Journal of Gastroenterology.
Related Links:
Ho Chi Minh University of Medicine
Serim Research Co.
Otsuka Pharmaceutical Co.
Several methods to diagnose H. pylori infection have been developed, among which the urea breath test (UBT) is currently regarded as the most accurate assay, but the UBT is still expensive and not widely available in many countries.
Scientists at the Ho Chi Minh City Medicine and Pharmacy University (Vietnam) working with Japanese colleagues, enrolled 200 patients undergoing upper gastrointestinal endoscopy from October 2012 to December 2012. Three biopsies were taken from each patient: two for histologic examination and one for the rapid urease test (RUT).
The biopsy for RUT was taken from the greater curvature of the corpus, about 2 cm above the atrophic border. This biopsy location has been reported to optimize the sensitivity of the PyloriTek RUT to detect H. pylori (Serim Research Co.; Elkhart, IN, USA). Urine samples were collected and were processed within one hour of collection for the detection of antibodies against H. pylori using the Rapirun Helicobacter pylori Antibody Stick (Otsuka Pharmaceutical Co., Ltd.; Tokyo, Japan). The test measures human immunoglobulin G (IgG) antibodies against H. pylori in urine using the principle of immunochromatography.
Of the 200 patients, 111 (55.5%) were diagnosed as being H. pylori positive. The sensitivity, specificity, and accuracy of the Rapirun Stick test were 84.7%, 89.9%, and 87.0%, respectively. There were 17 (8.5%) false-negative patients and 9 (4.5%) false-positive patients. Of the 24 patients with gastro-duodenal ulcer, 22 (91.7%) had H. pylori infection. However, 7 of 22 (31.8%) patients with reflux esophagitis also had the infection.
The authors demonstrated the usefulness of the Rapirun Stick test for the diagnosis of H. pylori infection in a Vietnamese population and the sensitivity, specificity, and accuracy of the Rapirun Stick test were high. In several patients, RUT and histologic examination produced false-negative or false-positive results, leading to the possible misdiagnosis of H. pylori infection. The study was published on May 7, 2014, in the World Journal of Gastroenterology.
Related Links:
Ho Chi Minh University of Medicine
Serim Research Co.
Otsuka Pharmaceutical Co.
Latest Immunology News
- Point-of-Care Tests Could Expand Access to Mpox Diagnosis
- T-Cell Senescence Profiling May Predict CAR T Responses
- Finger-Prick Lateral Flow Test Detects Sepsis Biomarkers at Point of Care
- Study Highlights Low Sensitivity of Current Lyme Tests in Early Infection
- Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
- Study Finds Influenza Often Undiagnosed in Winter Deaths
- Combined Screening Approach Identifies Early Leprosy Cases
- Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
- FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
- Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
- Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
- Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
- Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
- New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
- Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
- Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Channels
Clinical Chemistry
view channel
Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
Dementia affects more than 57 million people worldwide and is projected to nearly double within two decades, straining health systems and families. While biomarkers now enable accurate identification of... Read more
Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
High blood pressure during pregnancy is common and can progress to pre-eclampsia, making close monitoring at antenatal visits essential. However, most risk assessment begins only after pregnancy has started.... Read moreMolecular Diagnostics
view channel
Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response
Immunotherapy has transformed cancer care, yet durable benefit remains limited to a subset of patients, and clinicians still lack reliable tools to predict response before treatment begins.... Read more
Multiplex Respiratory Panel Integrates Automated Extraction to Streamline High-Volume Testing
Respiratory infections drive heavy testing volumes in clinical laboratories, where accurate, timely results across multiple pathogens are essential. Many labs are seeking to streamline workflows and increase... Read more
Whole-Blood RNA Test Predicts Disease Trajectory and Treatment Response
Clinicians often must predict whether acutely ill patients will recover or deteriorate despite limited time and clinical evidence. Earlier prognostic information could improve triage and guide treatment... Read more
Blood-Based Epigenetic Test Predicts GLP-1 Response and Tracks Treatment Effects
Prescriptions for GLP-1 medicines for weight loss are expanding rapidly, yet clinicians still lack scalable tools to predict biological response before treatment or monitor drug-driven changes beyond the scale.... Read moreHematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read moreImmunology
view channel
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read more
T-Cell Senescence Profiling May Predict CAR T Responses
Chimeric antigen receptor (CAR) T-cell therapy can deliver striking, durable remissions, yet many patients experience minimal or no benefit. The quality of patient-derived cytotoxic T lymphocytes used... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreTechnology
view channel
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read more
New Platform Captures Extracellular Vesicles for Early Cancer Detection
Early diagnosis remains the most effective way to reduce cancer mortality, yet many screening tools miss disease at its earliest stages. Biomarkers shed by tumors into blood and other fluids can be scarce... Read moreIndustry
view channel








